...
首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the nmri-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamat
【24h】

S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the nmri-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamat

机译:nmri-运动型-小鼠模型中的S-2-戊基-4-戊酸异羟肟酸及其代谢产物s-2-戊基-4-戊二酸:进一步的丙戊酸异羟肟酸酯的药代动力学特征,致畸作用和组蛋白脱乙酰基酶抑制能力

获取原文
获取原文并翻译 | 示例
           

摘要

Structure-activity relationship studies of valproic acid (VPA) derivatives have revealed a quantitative correlation between histone deacetylase (HDAC) inhibition and induction of neural tube defects (NTDs) in the NMRI-exencephaly-mouse model, but this correlation has been, so far, limited to congeners with a carboxylic acid function. Whereas the classical HDAC inhibitor trichostatin A is active only as a hydroxamate but not as a carboxylic acid, we found that neither VPA amides nor hydroxamates inhibit HDACs, but can cause NTDs; e.g., 2-pentyl-4-pentynoic hydroxamic acid with its S-enantiomer being the potent teratogen. We therefore investigated the hypothesis that hydroxamic acid derivatives of VPA might be metabolized in vivo and may possibly be pro-teratogenic, as had been shown for valpromide but not valproic hydroxamic acid. We developed two stereoselective quantification methods based on chiral derivatization of VPA hydroxamates with (1R,2S,5R)-(-)-menthylchloroformate and carboxylic acid derivatives with (S)-(-)-1-naphthylethylamine, followed by gas chromatography-nitrogen phosphor detector analysis of biological samples. We then determined the pharmacokinetic profiles of S-2-pentyl-4-pentynoic hydroxamic acid and of S-2-pentyl-4-pentynoic acid in mice. S-2-Pentyl-4-pentynoic hydroxamic acid was found to be extensively metabolized to the corresponding carboxylic acid without affecting the stereochemistry at position C2. Furthermore, the metabolite S-2-pentyl-4-pentynoic acid was found to be very stable in vivo, with an extended half-life of 4.2 h compared with that of VPA, 1.4 h. Comparison of the individual HDAC inhibition abilities of additional VPA amides and hydroxamates, as measured by cellular and enzymatic assays, led us to the conclusion that both classes of VPA derivatives can be pro-teratogenic.
机译:丙戊酸(VPA)衍生物的构效关系研究表明,在NMRI脑电图小鼠模型中,组蛋白脱乙酰基酶(HDAC)抑制与神经管缺损(NTD)诱导之间存在定量相关性,但到目前为止,这种相关性一直存在仅限于具有羧酸功能的同类物。传统的HDAC抑制剂曲古抑菌素A仅作为异羟肟酸酯有活性,而对羧酸无效,但我们发现VPA酰胺和异羟肟酸酯均不能抑制HDAC,但会引起NTD。例如,2-戊基-4-戊炔酸异羟肟酸及其S-对映体是有效的致畸剂。因此,我们研究了以下假设:VPA的异羟肟酸衍生物可能在体内被代谢,并且可能具有致畸性,如关于丙戊酰胺而不是丙戊酸异羟肟酸所显示的。我们基于VPA异羟肟酸酯与(1R,2S,5R)-(-)-薄荷基氯甲酸酯和羧酸衍生物与(S)-(-)-1-萘乙胺的手性衍生,然后通过气相色谱-氮气,开发了两种立体选择性定量方法荧光检测器分析生物样品。然后,我们确定了S-2-戊基-4-戊炔酸异羟肟酸和S-2-戊基-4-戊炔酸在小鼠中的药代动力学特征。发现S-2-戊基-4-戊酸异羟肟酸被广泛代谢为相应的羧酸,而不影响位置C2处的立体化学。此外,发现代谢物S-2-戊基-4-戊酸在体内非常稳定,半衰期为4.2小时,而VPA为1.4小时。通过细胞和酶法测定,比较其他VPA酰胺和异羟肟酸酯对HDAC的抑制能力,得出以下结论:这两类VPA衍生物均可致畸变。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号